A detailed history of Vanguard Group Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,479,210 shares of ATNM stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,479,210
Previous 1,446,326 2.27%
Holding current value
$2.63 Million
Previous $11.3 Million 3.34%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.56 - $9.89 $215,719 - $325,222
32,884 Added 2.27%
1,479,210 $10.9 Million
Q1 2024

May 10, 2024

BUY
$5.0 - $9.2 $410,565 - $755,439
82,113 Added 6.02%
1,446,326 $11.3 Million
Q4 2023

Feb 14, 2024

BUY
$4.02 - $6.08 $91,109 - $137,797
22,664 Added 1.69%
1,364,213 $6.93 Million
Q3 2023

Nov 14, 2023

BUY
$5.91 - $7.37 $42,947 - $53,557
7,267 Added 0.54%
1,341,549 $7.94 Million
Q2 2023

Aug 14, 2023

BUY
$7.15 - $9.39 $360,231 - $473,086
50,382 Added 3.92%
1,334,282 $9.9 Million
Q1 2023

May 15, 2023

BUY
$8.51 - $14.26 $1.42 Million - $2.38 Million
166,849 Added 14.94%
1,283,900 $12.1 Million
Q4 2022

Feb 10, 2023

BUY
$7.05 - $14.41 $339,133 - $693,178
48,104 Added 4.5%
1,117,051 $11.9 Million
Q2 2022

Aug 12, 2022

BUY
$4.71 - $7.11 $989,618 - $1.49 Million
210,110 Added 24.46%
1,068,947 $5.14 Million
Q1 2022

May 13, 2022

SELL
$4.57 - $6.4 $30,856 - $43,212
-6,752 Reduced 0.78%
858,837 $4.39 Million
Q4 2021

Feb 14, 2022

SELL
$6.01 - $8.8 $6,863 - $10,049
-1,142 Reduced 0.13%
865,589 $5.2 Million
Q3 2021

Nov 12, 2021

BUY
$5.76 - $9.67 $271,232 - $455,350
47,089 Added 5.75%
866,731 $7.68 Million
Q2 2021

Aug 13, 2021

BUY
$7.01 - $8.63 $5.75 Million - $7.07 Million
819,642 New
819,642 $6.48 Million

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $44.8M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.